|
Vaccine Detail
UV-Inactivated SARS-CoV + TLR Agonist Vaccine |
Vaccine Information |
- Vaccine Name: UV-Inactivated SARS-CoV + TLR Agonist Vaccine
- Target Pathogen: SARS-CoV
- Target Disease: Severe Acute Respiratory Syndrome (SARS)
- Type: Inactivated or "killed" vaccine
- Status: Licensed
- Host Species for Licensed Use: None
- Host Species as Laboratory Animal Model: mouse
- Antigen: whole virus (Iwata-Yoshikawa et al., 2014)
- Immunization Route: subcutaneous injection
- Description: Ultraviolet radiation is used to inactivate SARS-CoV and a Toll-Like Receptor Agonist Adjuvant is added to prevent eosinophilic immunopathology (Iwata-Yoshikawa et al., 2014).
|
Host Response |
Mouse Response
- Host Strain: BALB/c
- Host age: 10 weeks (Iwata-Yoshikawa et al., 2014)
- Host gender: Female (Iwata-Yoshikawa et al., 2014)
- Vaccination Protocol: 10 μg of UV-Inactivated SARS-CoV + TLR Agonist Vaccine subcutaneously injected in back and reimmunized 6 to 7 weeks later (Iwata-Yoshikawa et al., 2014)
- Immune Response: Induced neutralizing antibodies (More than in UV-V), Lymphocyte infiltration, High levels of CXCL10 and CXCL1, Production of IFN-β, Upregulation of TNF-α1 (Iwata-Yoshikawa et al., 2014)
- Side Effects: Minor eosinophil lung infiltration (Iwata-Yoshikawa et al., 2014)
- Challenge Protocol: 10 week old BALB/c mice were vaccinated with 10 μg UV-V and boosted 6 weeks later. Four weeks afterwards, the animals were inoculated in the left nostril with 106.5 TCID50 in 30 μl of F-musX(Iwata-Yoshikawa et al., 2014)
- Efficacy: All mice survived challenge (Iwata-Yoshikawa et al., 2014).
|
References |
Iwata-Yoshikawa et al., 2014: Iwata-Yoshikawa N, Uda A, Suzuki T, Tsunetsugu-Yokota Y, Sato Y, Morikawa S, Tashiro M, Sata T, Hasegawa H, Nagata N. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. Journal of virology. 2014; 88(15); 8597-8614. [PubMed: 24850731].
|
|